Navigation Links
Orexigen(R) Therapeutics Appoints Wendy Dixon, Ph.D. to Board of Directors
Date:4/21/2010

SAN DIEGO, April 21 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced the appointment of Wendy Dixon, Ph.D. to its board of directors.  Dr. Dixon brings 30 years of pharmaceutical development and commercial experience to the Orexigen board.  This experience includes commercialization strategy, new product launches and portfolio evaluation in cardiometabolic and primary care markets with Bristol-Myers Squibb Company (BMS), Merck, and SmithKline & French (now a part of GlaxoSmithKline).  Most recently, she was the President of Global Marketing and Chief Marketing Officer at BMS Company.

"Having submitted the New Drug Application for Contrave, we are now highly focused on the regulatory review process, establishing our commercial plans, and seeking a partner for our obesity products," said Michael Narachi, President and Chief Executive Officer of Orexigen. "Wendy brings extensive commercial experience in primary care that will be valuable as we prepare for the approval and launch of Contrave®."

"Orexigen has emerged as a leader in the development of obesity therapies in a time where there is a tremendous unmet need," added Dr. Dixon. "I look forward to being part of the Orexigen board and supporting the Company's vision of providing obese patients with important new treatment options."

Prior to joining BMS, Dr. Dixon held executive management positions at Merck, most recently serving as Senior Vice President of Marketing.  Dr. Dixon has also held executive management positions with Osteotech
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
7. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
8. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
9. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
10. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
11. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- Amgen (NASDAQ: AMGN ) today announced financial ... results include: , Total revenues increased 4 ... $5,370 million, with 6 percent product sales growth ... ® (denosumab), Sensipar ® (cinacalcet), Kyprolis ... Unfavorable changes in foreign exchange rates impacted total ...
(Date:7/30/2015)... , July 30, 2015 Tianyin Pharmaceutical Inc. ... company that specializes in the patented biopharmaceutical, modernized traditional ... (API), provided updates regarding the notice it received on ... "Exchange") indicating that the Company was below certain of ... Sections 134 and 1101 of the NYSE MKT Company ...
(Date:7/30/2015)... N.J. , July 30, 2015  Growth of ... switches as they bring former prescription users to the ... Kline forecasts robust Rx-to-OTC switch activity over ... categories emerging along with many new brands entering the ... occur over the next five years (even those with ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... 94 Percent of Men Maintained Normal Testosterone Levels Throughout ... ... 92 Percent of Men Expressed Satisfaction with NEBIDO, LEXINGTON, Mass., ... data on NEBIDO(R),(testosterone undecanoate), an investigational, long-acting intramuscular,injection for the treatment of ...
... Del., May 20 A new 12-week,study(2) ... maintenance,combination asthma therapy, SYMBICORT(R) (budesonide/formoterol fumarate,dehydrate) Inhalation ... in children ages 6 to 15 years ... corticosteroid (ICS).(2) Of note, the study included,efficacy ...
Cached Medicine Technology:Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association 2Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association 3Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association 4Study Analyzed SYMBICORT(R) in Children with Persistent Asthma 2Study Analyzed SYMBICORT(R) in Children with Persistent Asthma 3Study Analyzed SYMBICORT(R) in Children with Persistent Asthma 4Study Analyzed SYMBICORT(R) in Children with Persistent Asthma 5
(Date:7/31/2015)... , ... August 01, 2015 , ... Super Bowl 50 will emanate from ... League’s biggest day each year is the Super Bowl. In the two weeks that separate ... from the host venue. The 2016 Super Bowl game will mark the 50th time it ...
(Date:7/31/2015)... ... July 31, 2015 , ... Recently touted by Becker’s ... predictive health analytics , Jvion continues to disrupt the predictive analytic and big ... targets patient and population level illness to drive prevention and better health outcomes. ...
(Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics announces the ... Zeltiq Aesthetics released this new applicator in the United States as an upgrade ... outer thighs. The original applicator required a 2 hour treatment time. The ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... Group, Inc. has re-branded their social media profiles to better connect with the ... consumers to communicate, find information, share insights and opinions. The Rally Insurance Group, ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reliable source of ... catch a new and refreshing show on Broadway, look no further than Hamilton. This ... Obie Award, Outer Critics Circle Award, Drama Desk Award, Lucille Lortel Award, and New ...
Breaking Medicine News(10 mins):Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 4Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 5Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 6Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 7
... Human Services reported that very little precautionary measures can be ... flu) // . The infection in humans is actually caused ... ,Hence to prevent the global pandemic it has issued various ... a global pandemic. The government says that as such ...
... Guarraci, an assistance professor of psychology at south-western university and ... has a greater effect on the sexual behaviour of female ... and is among the first to determine the effects of ... also probes into the relationship between caffeine and sex. ...
... press that all the medical expenditures of pregnant women will be ... ,This plan is introduced mainly to ensure proper ... six months this plan will add $5 million to the annual ... the amount of expenditure of the rural women by $18. The ...
... of lives ever year. The need the organ, kidney is on ... ,Of all the organ transplantations done, kidney transplantation accounts ... sudden fall in the number of people who come forward to ... of the patients to undergo kidney transplants has widened to more ...
... Science Museum in London has found a unique way to help ... people the much-needed dose of light // . ,The ... of dark winter days. ,Up to 500,000 people, a ... seasonal affective disorder. SAD is more common in the northern ...
... an 8% increase in its share, following approval of Vivagel ... of HIV. // The company even signed a $20 ... and Infectious Diseases, an integral part of the National Institute ... for the prevention of HIV infection. The FDA recognizes the ...
Cached Medicine News:Health News:Starpharma Develops New Gel (Vivagel) To Prevent HIV Transmission 2
... Antigen-Antibody Pens-Using a proprietary and patented technology, ... pens, called Antigen-Antibody pens-TM, that will allow ... membranes in any form or shape or ... helps to see antigen being written on ...
... the Antigen-Antibody Pens-Using a proprietary and patented ... fountain pens, called Antigen-Antibody pens-TM, that will ... blotting membranes in any form or shape ... dyes helps to see antigen being written ...
... Store 200 to 350 Liters of ... Storage and Distribution of Purified Water,Millipores compact ... to store 200 to 350 liters of ... systems, and to maintain consistent purity of ...
... Liters of pure water, Complete, Compact Systems ... Water,Millipores compact S.D.S. Storage and Distribution Systems ... liters of purified water produced by Elix ... purity of stored water, provide effective protection ...
Medicine Products: